Trastuzumab Deruxtecan (DS8201) Rescue Advanced Her2 Low Expression Breast Cancer: A Case Report and Review of Literature

HER2 low-expression subtype breast cancer has not yet been included in the guidelines, so there are fewer drugs available for this type of breast cancer. The new drug Trastuzumab deruxtecan (DS8201) can be used for the treatment of HER2 low-expression subtype breast cancer, which is suitable for patients with non-surgically resectable or metastatic HER2 low-expression subtype breast cancer. We hereby report a case of using Trastuzumab deruxtecan to rescue an advanced HER2 low expression subtype breast cancer patient in our clinical admission process, in order to provide new treatment ideas for HER2 low expression patients.